Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 252 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phenylephrine Clear all
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis

NCT01848041
View directory record Official record
Conditions
Blepharoptosis
Interventions
RVL-1201, RVL-1201 Vehicle Placebo
Drug
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Morrow, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Cognition in Older Adults With Intermittent Hypoxia and Cognitive Training

NCT03957213
View directory record Official record
Conditions
Aging
Interventions
Acute Intermittent Hypoxia, Computerized Cognitive Training
Device · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
65 Years to 89 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 19, 2026, 1:19 AM EDT
Not listed Early Phase 1 Interventional

Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%

NCT06539637
View directory record Official record
Conditions
Cataract
Interventions
OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac}, Ketorolac Tromethamine {TORADOL} (0.5%) - Topical Eyedrop
Combination Product · Other
Lead sponsor
DHS Consulting
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Westbury, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 19, 2026, 1:19 AM EDT
Withdrawn Not applicable Interventional

Sphenopalatine Ganglion Block for Postdural Puncture Headache in the Emergency Department

NCT02517931
View directory record Official record
Conditions
Postdural Puncture Headache
Interventions
Sphenopalatine Ganglion Block, Placebo
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

NCT03751098
View directory record Official record
Conditions
Mydriasis
Interventions
Tropicamide/Phenylephrine ophthalmic solution (TR/PE), Placebo
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Early Phase 1 Interventional

Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study

NCT03719001
View directory record Official record
Conditions
Vascular Diseases
Interventions
Phenylephrine, Dexmedetomidine, Clevidipine, tetanic stimulus, Increased venous pressure, Calcium Chloride
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 19, 2026, 1:19 AM EDT
Terminated Phase 3 Interventional Results available

Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth

NCT01660893
View directory record Official record
Conditions
Anesthesia
Interventions
Tetracaine HCl 3% and oxymetazoline HCl 0.05%, Tetracaine HCl 3%, Placebo
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Baltimore, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Phase 4 Interventional Results available

No Drop Post-Op Cataract Surgery

NCT03864133
View directory record Official record
Conditions
Cataract
Interventions
Omidria
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 90 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Comparison of Inhalation vs. Intravenous Induction

NCT02331108
View directory record Official record
Conditions
Hypothermia
Interventions
Selection of anesthetic induction technique
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance

NCT04831047
View directory record Official record
Conditions
Ptosis, Eyelid, Conjunctiva Inflamed, Eye Manifestations
Interventions
Oxymetazoline hydrochloride 0.1% ophthalmic solution, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets

NCT01208155
View directory record Official record
Conditions
Bioavailability, Pharmacokinetics
Interventions
Fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects

NCT01691547
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC /VI, UMEC, VI, FF
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Phase 3 Interventional Results available

Study of Safety of RVL-1201 in Treatment of Blepharoptosis

NCT03536949
View directory record Official record
Conditions
Blepharoptosis
Interventions
RVL-1201, Vehicle ophthalmic solution
Drug · Other
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
9 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
35
States / cities
Phoenix, Arizona • Garden Grove, California • Mission Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02865668
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Phase 4 Interventional

Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery

NCT04316936
View directory record Official record
Conditions
Cataract Surgery
Interventions
Omidria, Dextenza (dexamethasone ophthalmic insert) 0.4mg, Dexycu, 9% Intraocular Suspension, Prednisolone Acetate 1%
Drug
Lead sponsor
Silverstein Eye Centers
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 19, 2026, 1:19 AM EDT
Terminated Not applicable Interventional Results available

Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy

NCT01982383
View directory record Official record
Conditions
Central Serous Chorioretinopathy
Interventions
Micropulse Laser Treatment, No treatment
Device · Other
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 19, 2026, 1:19 AM EDT
Recruiting No phase listed Observational

Cardiogenic Shock Working Group Registry

NCT04682483
View directory record Official record
Conditions
Cardiogenic Shock
Interventions
Vasopressor, Inotrope, Acute Mechanical Circulatory Support Devices
Drug · Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
16
States / cities
Weston, Florida • Chicago, Illinois • Portland, Maine + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 19, 2026, 1:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Deciphering Preserved Autonomic Function After Multiple Sclerosis

NCT07012135
View directory record Official record
Conditions
Multiple Sclerosis, Control Subjects, Autonomic Dysreflexia
Interventions
Tests of sympathetic inhibition, Tests of sympathetic activation, Testing of autonomic dysreflexia
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Phase 4 Interventional Results available

Preventing Hypotension in Parturients With an Elevated Body Mass Index (BMI)

NCT01481740
View directory record Official record
Conditions
Hypotension
Interventions
Phenylephrine bolus, phenylephrine infusion
Drug
Lead sponsor
IWK Health Centre
Other
Eligibility
18 Years and older · Female only
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Brimonidine

NCT03959176
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Brimonidine, Tropicamide, Phenylephrine Ophthalmic Product
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 19, 2026, 1:19 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY

NCT02665221
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
No Treatment Arm, Topical Preparation H arm
Other · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Phase 4 Interventional Results available

Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery

NCT03228914
View directory record Official record
Conditions
Endoscopic Sinus Surgery, Nasal Polyps
Interventions
Oxymetazoline, Epinephrine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers

NCT06137703
View directory record Official record
Conditions
Biological Availability
Interventions
Zavegepant 100mg non-enteric coated soft gel capsule, Zavegepant 100mg immediate release tablet, Zavegepant 2 x 100mg immediate release tablets, Zavegepant 4 x 25mg enteric coated soft gel capsule
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 19, 2026, 1:19 AM EDT
Completed Phase 2 Interventional

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

NCT01275105
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%, Oxymetazoline HCl 0.025%
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 19, 2026, 1:19 AM EDT